ReviewMedicine2026
Visual analysis of research status and hotspots of Pinellia ternata from 2004 to 2025: A bibliometric review.
Review in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pinellia ternata has been widely recognized as a traditional Chinese medicine for its use in digestive system diseases and cancers. Furthermore, its good clinical efficacy, excellent safety, and limited side effects have attracted growing interest from research institutions in China, South Korea, the United States, and Japan, resulting in a surge of associated studies. However, the information remains scattered, lacking systematic summaries. This makes it challenging to consolidate the extent of the research progress. Thus, in this study, data from published literature were obtained and assessed to assist researchers in comprehending the current research landscape in the field and to investigate research hotspots and emerging frontiers. Two English databases were employed to search and download the literature on P ternata research published from 2004 to 2025. We used VOSviewer, Microsoft Excel, and CiteSpace to visually analyze annual publishing trends, publishing countries, institutions, authors, journals, keywords, and references in the field. We retrieved 488 papers. Publications have increased annually, particularly in 2024. China, South Korea, the United States, and Japan take the lead in this field of research. Nanjing University of Chinese Medicine produced the largest number of papers. The Journal of Ethnopharmacology contained the most publications. The most prolific authors are Xue Jianping and Xue Tao. Keywords with the highest frequency were P. ternata, expression, banxia xiexin decoction, and network pharmacology. Twelve clusters and twenty-five burst keywords were generated. To date, 3 areas have been the primary subject of this field's research: research on related classic prescriptions and their applications, research on pharmacological components and mechanisms of action, and research on cultivation and quality control. Furthermore, research on microscopization, normalization, standardization, and objectification of traditional Chinese medicine has also been developing.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.